Login to Your Account

Largest European Biotech Series A for 2011

Amakem Gets $25M for Kinase Inhibitors for Ophthalmology

By Cormac Sheridan

Wednesday, September 7, 2011
In what may well be the largest Series A round in European biotechnology this year, Amakem NV raised €18 million (US$25.6 million) to fund development of a series of locally acting kinase inhibitors aimed at ophthalmology indications. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription